Abstract. To construct a non-clinical database for drug-induced QT interval prolongation, the electrophysiological effects of 11 positive and 10 negative compounds on action potentials (AP) in guinea-pig papillary muscles were investigated in a multi-site study according to a standard protocol. Compounds with a selective inhibitory effect on the rapidly activated delayed rectifier potassium current (I Kr ) prolonged action potential duration at 90% repolarization (APD 90 ) in a concentration-dependent manner, those showing Ca 2+ current (I Ca ) inhibition shortened APD 30 , and those showing Na + current (I Na ) inhibition decreased action potential amplitude (APA) and V max . Some of the mixed ion-channel blockers showed a bell-shaped concentration-response curve for APD 90 , probably due to their blockade of I Na and / or I Ca , sometimes leading to a falsenegative result in the assay. In contrast, all positive compounds except for terfenadine and all negative compounds with I Kr -blocking activity prolonged APD 30-90 regardless of their I Na -and / or I Ca -blocking activities, suggesting that APD 30-90 is a useful parameter for evaluating the I Krblocking activity of test compounds. Furthermore, the assay is highly informative regarding the modulation of cardiac ion channels by test compounds. Therefore, when APD 90 and APD 30-90 are both measured, the action potential assay can be considered a useful method for assessing the risk of QT interval prolongation in humans in non-clinical safety pharmacology studies. Supplementary material (Appendix): available only at http://dx
Abstract. To construct a non-clinical database for drug-induced QT interval prolongation, the electrophysiological effects of 11 positive and 10 negative compounds on action potentials (AP) in guinea-pig papillary muscles were investigated in a multi-site study according to a standard protocol. Compounds with a selective inhibitory effect on the rapidly activated delayed rectifier potassium current (I Kr ) prolonged action potential duration at 90% repolarization (APD 90 ) in a concentration-dependent manner, those showing Ca 2+ current (I Ca ) inhibition shortened APD 30 , and those showing Na + current (I Na ) inhibition decreased action potential amplitude (APA) and V max . Some of the mixed ion-channel blockers showed a bell-shaped concentration-response curve for APD 90 , probably due to their blockade of I Na and / or I Ca , sometimes leading to a falsenegative result in the assay. In contrast, all positive compounds except for terfenadine and all negative compounds with I Kr -blocking activity prolonged APD regardless of their I Na -and / orIntroduction During the past decade, a number of non-cardiovascular drugs have been required to have a warning on their label or have been withdrawn from the market because of excessive prolongation of the QT interval on the electrocardiogram, an effect that can lead to a rare but life-threatening polymorphic ventricular tachycardia called torsade de pointes (TdP). Since a wide variety of non-cardiovascular drugs prolong the QT interval (1 -4) , even though the relationship between QT interval prolongation and TdP has not yet been elucidated, QT interval prolongation is now a matter of concern to regulatory authorities, and it is considered a significant risk factor for predicting the human safety of new chemical entities (5, 6) . Accordingly, in 1997, the Committee for Proprietary Medicinal Products (CPMP) of the European Union published a 'points to consider' document that made recommendations for non-clinical and clinical approaches to assess the potential risk of QT interval prolongation by non-cardiovascular medicinal products (7), followed by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) S7B guideline (8) , in which an in vitro I Kr assay and an in vivo QT assay are recommended as a general non-clinical testing strategy for assessing the potential risk of QT interval prolongation.
In addition to the ion channel assay with isolated cardiac cells (9 -11) or cell lines transfected with a cloned human channel gene (11, 12) , the action potential (AP) assay with isolated cardiac tissues (13, 14) or enzymatically isolated single ventricular myocytes (10, 15) has been used to assess the potential for new chemical entities to delay ventricular repolarization. This assay has been generally thought to be a useful predictor of the risk for QT interval prolongation based on the fact that the action potential duration (APD) of each cardiac myocyte can be prolonged by proarrhythmic drugs (5, 16) , although there is serious criticism that some known proarrhythmic compounds cannot be detected when a parameter such as action potential duration at 90% repolarization (APD 90 ) is used as the index (17, 18) .
A project named "QT Interval Prolongation: Project for Database Construction (QT PRODACT)", which was organized by pharmaceutical companies belonging to the Japan Pharmaceutical Manufacturers Association (JPMA) and contract laboratories belonging to the Japan Association of Contract Laboratories for Safety Evaluation (JACL), designed several studies to construct a database of cardiac safety pharmacology, one of which was the AP assay in isolated guinea-pig papillary muscles using a conventional glass microelectrode technique. Although isolated canine Purkinje fibers or guinea-pig papillary muscles are commonly used for the AP assay (2, 4, 5) , the QT PRODACT decided on guinea-pig papillary muscles because they have the advantages of easier specimen handling and lower cost compared to canine Purkinje fibers. This article provides an overview of AP assays conducted by the QT PRODACT to examine 21 compounds, including 11 compounds reported to induce QT interval prolongation and associated ventricular arrhythmias such as TdP in humans ('positive compounds') and 10 compounds considered not to have such effects ('negative compounds'). The AP assay project has the following goals: 1) to construct a database of the AP parameters in isolated guinea-pig papillary muscles for the 21 compounds to support the practices of the ICH S7B guideline and contribute to the evaluation of new chemical entities under research and development, 2) to examine the usefulness of the AP assay by determining whether the positive compounds, including the mixed ion-channel blockers, caused changes in the configuration of the AP due to simultaneous blockade of two or more cardiac ion channels, and 3) to publish the reference baseline values of electrophysiological parameters in guinea-pig papillary muscles by analyzing data collected from experiments performed in multiple testing facilities in accordance with a standard protocol established by the QT PRODACT. Thus, this is the first prospective, multi-site study of the in vitro AP assay using guinea-pig papillary muscles.
This study is not intended to be used to evaluate the safety of these compounds in humans, but rather to provide a comparison of the effects of each compound on the in vitro repolarization assay under similar experimental conditions. The safety of each compound in the clinical setting should be assessed not from the results obtained in this study but by integrating non-clinical, clinical, and other relevant information relating to the compound.
Materials and Methods

Test compounds
A total of 21 compounds, including 11 positive and 10 negative compounds, were used (Table 2 ; also see Appendices 2-1 to 2-21 in the Supplemental Materials available with this article online). The positive compounds were astemizole, bepridil hydrochloride (bepridil), cisapride, disopyramide, E-4031, haloperidol, MK-499, pimozide, quinidine hydrochloride (quinidine), terfenadine, and thioridazine hydrochloride (thioridazine); and the negative compounds were amoxicillin, aspirin, captopril, ciprofloxacin hydrochloride (ciprofloxacin), diphenhydramine hydrochloride (diphenhydramine), flecainide hydrochloride (flecainide), lidocaine hydrochloride (lidocaine), nifedipine, dl-propranolol hydrochloride (propranolol), and verapamil hydrochloride (verapamil). Three or four concentrations of each test compound were examined in each AP assay. The applied concentrations for the positive compounds were based on preliminary experiments or previous studies demonstrating the maximum effects of APD prolongation, and those for the negative compounds were based on the maximum soluble concentration in vehicle or were set at a higher concentration than the therapeutic plasma concentration in humans.
Stock solutions of all test compounds were prepared daily by dissolving the compounds in dimethyl sulfoxide (DMSO) (except for ciprofloxacin, see Appendix 2-15), and then each stock solution was sequentially diluted to the proper concentrations with DMSO. These DMSOdiluted solutions were then diluted 1000-fold with Tyrode solution immediately before use to achieve the desired final concentrations as shown in Table 2 , so that the final concentration of DMSO in the perfusate was 0.1% (v / v).
Animals
Male Hartley guinea pigs (259 -503 g) were used. For further details of the body weight at the time of use and the supplier to each facility, see Appendices 2-1 to 2-21 in the Supplemental Materials. The protocols and the care of the animals complied with the Guiding Principles for the Care and Use of Laboratory Animals recommended by The Japanese Pharmacological Society and were approved by the animal care committee at each facility.
Standard protocol
Preparation and electrophysiology: Animals were anesthetized with diethyl ether (except for the testing of quinidine and diphenhydramine, see Appendices 2-9 and 2-16) and the hearts were quickly removed. Papillary muscles were dissected from the right ventricle in Tyrode solution aerated with a mixture of 95% O 2 and 5% CO 2 . The Tyrode solution had the following composition:
.0 mmol / L NaHCO 3 , and 11.1 mmol / L glucose. The papillary muscle preparations were fixed in an organ bath and superfused with the Tyrode solution (37.0 ± 0.5°C) aerated with the O 2 / CO 2 mixture at a flow rate of 5 -10 mL / min (except for the testing of aspirin, see Appendix 2-13). The preparation was stimulated by an electrical stimulator and electrodes through an isolation unit at 1.0 Hz with rectangular pulses of 1-ms duration at 1.5 -2.5 times the diastolic threshold. The transmembrane APs were recorded by glass microelectrodes (10 -40 MΩ) filled with 3 mol / L KCl and connected to a high-impedance amplifier. The APs were recorded on a personal computer and analyzed with an action potential recording / analysis system. For further details of the experimental conditions and equipment used at each facility, see Appendices 2-1 to 2-21 in the Supplemental Materials.
Measurement of AP parameters and data analysis: After an equilibrating period at the basal stimulation frequency of 1.0 Hz, the electrophysiological effects of vehicle or test compounds on the APs in papillary muscles were evaluated before and after a 30-min application period at 3 different stimulation frequencies, that is, the stimulation frequency was changed from 1.0 Hz to 0.5 Hz and then from 0.5 Hz to 2.5 Hz, with 2 -3 min at each stimulation frequency. For each measurement, 5 consecutive APs were recorded after the stabilizing period. During perfusion with the Tyrode solution containing vehicle or a test compound, the preparation was continuously stimulated at 1.0 Hz.
The parameters measured in this study were action potential duration at 30%, 60%, and 90% repolarization (APD 30 , APD 60 , and APD 90 , respectively); action potential amplitude (APA); maximum rate of rise of the action potential (V max ); and resting membrane potential (RMP). APD (triangulation parameter) was defined as the difference between APD 90 and APD 30 (19, 20) . Only preparations that satisfied the criteria RMP <−80 mV, APA >100 mV, V max >120 V/ s, and APD 90 >160 ms, when stimulated at 1.0 Hz, were used. When two or three preparations were isolated from the same animal, they were treated with different concentrations of test compound.
Statistics: The absolute baseline values of AP parameters were expressed as the mean ± S.D. Statistical differences were evaluated by Tukey's test for comparison between multiple groups. To evaluate the effects of test compounds on AP parameters, percent change from the pre-treatment value was calculated and expressed as the mean ± S.E.M. of six preparations for each test compound at each concentration. Statistical differences were evaluated by Dunnett's test for comparison with the vehicle-control group. Differences were considered significant at P<0.05.
Results
The baseline values of AP parameters in isolated guinea-pig papillary muscles at stimulation frequencies of 0.5, 1.0, and 2.5 Hz pooled from 636 action potentials, collected from 21 testing facilities, are shown in Table 1 . APD 30 , APD 60 , and APD 90 significantly shortened in a frequency-dependent manner, but the difference between 0.5 Hz and 1.0 Hz was slight. APA also decreased in a frequency-dependent manner. RMP and V max showed a tendency to decrease in a frequency-dependent manner. In contrast, there was no frequency-dependent change in APD . with a maximum prolongation of 3% at 10 µmol / L (Fig. 2) . Similar effects on these parameters were observed at 0.5 Hz, whereas at 2.5 Hz the shortening of APD 30 was attenuated and a pronounced prolongation of APD 90 was observed at 10 µmol / L or more. At a stimulation frequency of 1.0 Hz, bepridil markedly prolonged APD 30-90 in a concentration-dependent manner; the changes in APD 30-90 at 10 and 100 µmol / L were 19% and 29%, respectively. Similar concentration-dependent prolongation of APD was observed at 0.5 and 2.5 Hz. Bepridil at 100 µmol / L decreased APA and V max in a frequency-dependent manner. Bepridil did not affect RMP.
Cisapride (0.01, 0.1, and 1 µmol/ L; Fig. 2 , Appendices 1-3 and 2-3): At a stimulation frequency of 1.0 Hz, cisapride prolonged APD 60 and APD 90 in a concentration-dependent manner; the changes in APD 60 and APD 90 were 10% and 9%, respectively, at 0.1 µmol / L and 17% and 18%, respectively, at 1 µmol / L. Cisapride also prolonged APD 30-90 by 12% and 38% at 0.1 and 1 µmol / L, respectively. Similar degrees of prolongation of these parameters were observed at 0.5 and 2.5 Hz. Cisapride did not exhibit obvious reverse frequencydependent prolongation of the APD in guinea-pig papillary muscles, nor did it affect RMP, APA, or V max .
Disopyramide (1, 3, and 30 µmol/ L; Appendices 1-4 and 2-4): At a stimulation frequency of 1.0 Hz, disopyramide showed bell-shaped concentration-response relationships for APD 30 , APD 60 , and APD 90 with a maximum prolongation at 3 µmol / L. Similar bell-shaped concentration-response curves for these parameters were observed at 0.5 Hz, but the curves of these parameters became shallow at 2.5 Hz. At a stimulation frequency of 1.0 Hz, disopyramide prolonged APD 30-90 by 21% and 36% at 3 and 30 µmol / L, respectively. Similar degrees of prolongation of APD were observed at 0.5 Hz and to a lesser extent at 2.5 Hz. Disopyramide at 30 µmol / L decreased APA and V max in a non-frequency-dependent manner; and at the same concentration, it slightly depolarized RMP at 1.0 Hz only. 30 , APD 60 , and APD 90 at 0.01 µmol / L were 5%, 7%, and 7%, respectively; and at 0.1 µmol / L, they were 14%, 26%, and 27%, respectively. E-4031 also prolonged APD 30-90 by 13% and 59% at 0.01 and 0.1 µmol / L, respectively (Fig. 2) . Since similar degrees of prolongation of these parameters were observed at 0.5 Hz despite lesser degrees of prolongation at 2.5 Hz, E-4031 did not cause any obvious reverse frequency-dependent prolongation of the AP duration in guinea-pig papillary muscles. E-4031 at 0.1 µmol / L slightly but significantly increased APA at both 1.0 and 2.5 Hz. E-4031 did not affect V max or RMP.
Haloperidol (0.1, 1, and 10 µmol/ L; Appendices 1-6 and 2-6): At a stimulation frequency of 1.0 Hz, haloperidol concentration-dependently prolonged APD 30 , APD 60 , and APD 90 : the changes in APD 30 , APD 60 , and APD 90 at 1 µmol / L were 12%, 12%, and 11%, respectively; and at 10 µmol / L, they were 13%, 20%, and 21%, respectively. Similar degrees of prolongation of these parameters were observed at 0.5 and 2.5 Hz.
Haloperidol at the highest concentration of 10 µmol / L prolonged APD 30-90 by 51%, 43%, and 36% at 0.5, 1.0, and 2.5 Hz, respectively. Haloperidol at 10 µmol / L decreased V max by 7%, 8%, and 17% at 0.5, 1.0, and 2.5 Hz, respectively. The compound did not affect APA or RMP. MK-499 (0.01, 0.1, and 1 µmol/L; Appendices 1-7 and 2-7): At a stimulation frequency of 1.0 Hz, MK-499 showed a tendency to prolong APD 30 , and it concentration-dependently prolonged APD 60 and APD 90 ; the changes in APD 60 and APD 90 at 0.1 µmol / L were both 14%, and they at 1 µmol / L were both 26%. MK-499 prolonged APD in a concentration-dependent manner; the changes in APD 30-90 at 0.1 and 1 µmol / L were 20% and 49%, respectively. Similar prolongation of APD 60 , APD 90 , and APD was observed at 0.5 and 2.5 Hz, but the degree of prolongation of these parameters was more prominent at the lower stimulation frequency. MK-499 did not affect RMP, APA, or V max .
Pimozide (0.1, 1, and 10 µmol /L; Appendices 1-8 and 2-8): Pimozide at concentrations up to 10 µmol / L did not prolong APD 90 at any stimulation frequency tested. Pimozide at the highest concentration of 10 µmol / L slightly shortened APD 30 by 3% and 4% at 1.0 and 2.5 Hz, respectively. In contrast, pimozide at 10 µmol / L prolonged APD 30-90 by 9%, 9%, and 10% at 0.5, 1.0, and 2.5 Hz, respectively. Pimozide decreased V max only at the lowest concentration of 0.1 µmol / L at 0.5 and 1.0 Hz, and it had no effect on RMP or APA.
Quinidine (1, 10, and 100 µmol/L; Fig. 2 , Appendices 1-9 and 2-9): At a stimulation frequency of 1.0 Hz, quinidine shortened APD 30 by 16% at the highest concentration of 100 µmol / L. Quinidine showed bellshaped concentration-response relationships for APD 60 and APD 90 , with the maximum prolongation at Thioridazine (0.1, 1, and10 µmol/L; Appendices 1-11 and 2-11): At a stimulation frequency of 1.0 Hz, thioridazine prolonged APD 60 and APD 90 , causing increases in APD 60 and APD 90 at 1 µmol / L of 5% and 5%, respectively, and at 10 µmol / L, increases of 7% and 11%, respectively. Almost identical degrees of prolongation of these parameters were observed at 0.5 and 2.5 Hz. Thioridazine at 10 µmol / L prolonged APD by 39%, 34%, and 38% at 0.5, 1.0, and 2.5 Hz, respectively. Thioridazine at 10 µmol / L decreased APA at 0.5 and 2.5 Hz, but decreased V max at 2.5 Hz only. At 10 µmol / L only, the compound slightly depolarized RMP at 2.5 Hz.
Negative compounds
Amoxicillin (27, 270 , and 2700 µmol /L; Appendices 1-12 and 2-12): At stimulation frequencies of 0.5 and 1.0 Hz, amoxicillin up to 2700 µmol / L had no effect on any of the AP parameters. At a stimulation frequency of 2.5 Hz, only the highest concentration of amoxicillin, 2700 µmol / L, slightly decreased V max without affecting the other parameters.
Aspirin (100, 1000, and 10000 µmol/L; Appendices 1-13 and 2-13): Aspirin up to 10000 µmol / L had no effect on any of the AP parameters at any stimulation frequency.
Captopril (1, 10, and 100 µmol/L; Fig. 4 , Appendices 1-14 and 2-14): Captopril at concentrations up to 100 µmol / L had no effect on any of the AP parameters at any stimulation frequency except for APD 30 at 1 µmol / L and 2.5 Hz.
Ciprofloxacin (1, 10, and 100 µmol/L; Figs. 3 and 4, Appendices 1-15 and 2-15): Representative recordings of the electrophysiological effect of 1 -100 µM ciprofloxacin are shown in Fig. 3 . At a stimulation frequency of 1.0 Hz, ciprofloxacin at the highest concentration of 100 µmol / L slightly prolonged APD 30 , APD 60 , and APD 90 by less than 3%. Similar degrees of prolongation of these parameters were observed at 0.5 and 2.5 Hz. Ciprofloxacin at 100 µmol / L prolonged APD by about 5% at every stimulation frequency tested. The compound did not affect RMP, APA, or V max .
Diphenhydramine (0.3, 3, and 30 µmol /L; Appendices 1-16 and 2-16): At a stimulation frequency of 1.0 Hz, diphenhydramine at the highest concentration of 30 µmol / L shortened APD 30 , APD 60 , and APD 90 by about 10%. Similar decreases in these parameters were observed at 0.5 and 2.5 Hz. In contrast, diphenhydramine prolonged APD 30-90 in a reverse frequencydependent manner: the changes in APD 30-90 at 3 µmol / L were 12%, 8%, and 0% at 0.5, 1.0, and 2.5 Hz, respectively; and at 30 µmol / L they were 8%, 5%, and −2% at 0.5, 1.0, and 2.5 Hz, respectively. Diphenhydramine up to 30 µmol / L did not affect RMP, APA, or V max .
Flecainide (1, 3, and 10 µmol/L; Appendices 1-17 and 2-17): Flecainide at the highest concentration of 10 µmol / L prolonged APD 90 by more than 5% at 1.0 and 2.5 Hz. Flecainide prolonged APD 30-90 in a reverse frequency-dependent manner: at 3 µmol / L or more it prolonged APD 30-90 by more than 10% at 0.5 Hz and by more than 5% at 1.0 Hz, but it did not prolong APD 30-90 at 2.5 Hz at any concentration tested. Flecainide at 10 µmol / L slightly decreased APA at 0.5 Hz. Flecainide decreased V max in a frequency-dependent manner. At 2.5 Hz, a marked reduction in V max was observed at 3 µmol / L or more, and the reduction induced by 10 µmol / L flecainide increased with increasing stimulation frequency. The compound did not affect RMP.
Lidocaine (1, 10, and 100 µmol/L; Fig. 4 , Appendices 1-18 and 2-18): Lidocaine at the highest concentration of 100 µmol / L shortened APD 30 , APD 60 , and APD 90 by 7% -24% at 0.5, 1.0, and 2.5 Hz. At 100 µmol / L, it decreased V max by 7% and 11% at 1.0 and 2.5 Hz, respectively. Lidocaine did not affect APA except at 100 µmol / L and 0.5 Hz; and at concentrations up to 100 µmol / L, it had no effect on APD by more than about 10% and decreased APA by more than 5% at every stimulation frequency tested. Propranolol also decreased V max in a frequency-dependent manner. The reduction in V max at 30 µmol / L was 10%, 19%, and 43% at 0.5, 1.0, and 2.5 Hz, respectively. The compound had no effect on RMP except at 30 µmol / L and 2.5 Hz.
Verapamil (1, 10, and 100 µmol/L; Fig. 4 , Appendices 1-21 and 2-21): At a stimulation frequency of 1.0 Hz, verapamil shortened APD 30 and APD 60 in a concentration-dependent manner: the respective changes at 10 µmol / L were 20% and 7%, and at 100 µmol / L, they were 52% and 36%. Similar decreases in these parameters were observed at 0.5 and 2.5 Hz. Verapamil at 100 µmol / L also shortened APD 90 by 20%, 25%, and 26% at 0.5, 1.0, and 2.5 Hz, respectively. In contrast, verapamil at 0.5 and 1.0 Hz prolonged APD in a concentration-dependent manner (Fig. 4) . Verapamil at 100 µmol / L caused reverse frequency-dependent prolongation of APD ; at 10 µmol / L or more, it decreased APA; and at 100 µmol / L, it decreased V max at every stimulation frequency tested. The reduction in APA and V max observed at 2.5 Hz was greater than that observed at 0.5 or 1.0 Hz. The compound did not affect RMP.
Discussion
The QT PRODACT project consists of several studies, including studies on an in vitro AP assay and four in vivo QT assays with conscious beagle dogs, cynomolgus monkeys, and miniature pigs and with anesthetized dogs. For the in vitro AP assay, the electrophysiological effects of 21 compounds on cardiac APs were investigated in guinea-pig papillary muscles by means of a conventional glass microelectrode technique. Each experiment was performed at 21 testing facilities in accordance with a standard protocol established by the QT PRODACT, a protocol that is similar to the routine protocol used in safety pharmacology studies. To our knowledge, this is the first prospective, multi-site study of the in vitro AP assay using guinea-pig papillary muscles.
Reference values of AP parameters in guinea-pig papillary muscle
There have been numerous reports on the AP assay in guinea-pig papillary muscles using the conventional microelectrode technique, but reference baseline values for the AP parameters have not been established because the different testing facilities employed various extracellular K + concentrations, experimental temperatures, or animals of different ages. Establishment of baseline values under standardized conditions is necessary because RMP directly depends on the extracellular K + concentration (21), APD in guinea-pig papillary muscles is markedly affected by the temperature (22) , and agerelated changes in APD are observed in various cardiac tissues (23, 24) .
The QT PRODACT collected data on 636 action potentials from 21 different testing facilities, from which the baseline values analyzed were thought to include both intra-and inter-facility variability. This is supported by the results reported by Yamazaki et al. (25) who conducted a survey focused on the intra-and interfacility variability in the AP assay as a QT PRODACT study. Therefore, similar action potential data should be obtainable in any of the testing facilities when the AP assay in guinea-pig papillary muscles is performed under conditions in which both the testing protocol and the experimental conditions are similar to those recommended by the QT PRODACT.
In the APs recorded prior to the application of vehicle or 21 test compounds, AP durations and APA and, to a lesser extent, V max significantly decreased; and RMP depolarized in proportion to the increase in stimulation frequency (Table 1) . These frequency-dependent changes in the AP parameters were observed as a physiological response similar to those reported previously (26, 27) . In contrast, APD did not show any dependence on the stimulation frequency, presumably because APD represents the difference between APD 30 and APD 90 , each of which might be subject to similar frequencydependent changes that would not be observed in the triangulation parameter APD .
Potential significance of APD The AP assay has been widely used as an experimental tool for evaluating the potential risk of QT interval prolongation by new chemical entities (2, 4, 5) . Since the QT interval is the sum of the duration of depolarization and the duration of repolarization in individual ventricular cells, APD 90 , one of the traditional parameters of the cardiac AP, is routinely measured as an index of the duration of repolarization (4, 5) . In the present study, 7 out of the 11 positive compounds, cisapride, disopyramide, E-4031, haloperidol, MK-499, quinidine, and thioridazine, significantly prolonged APD 90 by more than 10% in isolated guinea-pig papillary muscles (Table 2) . These compounds are known to prolong the QT interval and / or to induce TdP in humans (1, 2, 4) . Therefore the measurement of APD 90 in isolated guinea-pig papillary muscles is useful for assessing the potential risk that new chemical entities will cause delayed ventricular repolarization in humans.
However, some questions concerning the usefulness of APD 90 arise from evidence that some known proarrhythmic compounds have failed to be detected by the prolongation of APD 90 in a similar assay (17, 18) . In fact, we found that among the positive compounds tested, pimozide and terfenadine did not prolong APD 90 (Table 2) . Quinidine and disopyramide, typical mixed ion-channel blockers, significantly prolonged APD 90 , but the degree of prolongation was attenuated at higher concentrations, showing a bell-shaped concentrationresponse relationship. This may arise from the fact that many ion channels closely associated with the repolarization phase of cardiac APs contribute to the formation of APD 90 (1 -3) . Thus, an alternative parameter capable of revealing the modulation of ion channels by drugs should be employed when guinea-pig cardiac preparations are used for assessing the potential risk of druginduced QT interval prolongation in humans. Accordingly, the novel triangulation parameter, which is measured as APD in this study, was introduced in the QT PRODACT as an index specifically responsive to the effect of drugs on delayed rectifier potassium current (I K ), especially rapidly activated delayed rectifier potassium current (I Kr ). The parameter is calculated as the difference between APD 90 and APD 30 [see Kii et al. (20) for further details].
Astemizole and bepridil slightly prolonged APD 90 and pimozide had no effect on APD 90 even at the highest concentration (10 µmol/L). In contrast, these compounds significantly prolonged APD at the same or lower concentrations. Astemizole, bepridil, and pimozide are reported to prolong the QT interval in humans (1, 4) , presumably due to human ether-a-go-go-related gene (hERG) channel blocking activity (28 -30) . Therefore, it is possible that APD 30-90 would be a useful index for assessing whether a test compound would be likely to suppress I Kr or hERG K + current, even though APD failed to detect the hERG blocking activity of terfenadine, as discussed below. Five of the ten negative compounds, ciprofloxacin, diphenhydramine, flecainide, propranolol, and verapamil, prolonged APD 30-90 at their extremely high concentrations, which are reported to suppress hERG K + currents (31 -35) . The other negative compounds, amoxicillin, aspirin, captopril, nifedipine, and lidocaine, did not prolong APD at all. Amoxicillin, aspirin, captopril, and nifedipine have little or no effect on hERG K + current (5, 35 -37) , and lidocaine modestly suppresses it with an IC 50 value of 263 µmol / L (34); these data suggest that the prolongation of APD 30-90 by the negative compounds resulted from inhibition of hERG K + current. Thus, APD 30-90 seems to be superior to APD 90 as an index for detecting the hERG-blocking activity of test compounds (20) .
In this study, we categorized flecainide, a Class Ic antiarrhythmic, as a negative compound. This was based on previous reports indicating that flecainide has only minor effects on APD prolongation (38) , that widecomplex ventricular tachycardia is the most common serious ventricular arrhythmia provoked by flecainide, and that TdP is extremely uncommon (39) . Recently, however, flecainide-induced TdP has been described in case reports (40, 41) , presumably due to its hERG / I Krblocking activity (34) . Therefore, it may be considered that the classification of flecainide has not been adequately settled, although this compound is taken as a negative compound in the present study.
Usefulness of the AP assay
Cardiac APD is controlled by a small net current resulting from a delicate balance between inward and outward currents during the plateau repolarization phase. Since late Na + current (I Na ), Ca 2+ current (I Ca ), and I K are thought to play important roles during plateau repolarization, small changes in the conductance of these channels can significantly alter the APD. The effects of mixed ion-channel blockers on APD 90 are sometimes controversial (4, 17, 18) because their inhibitory actions on I Na and I Ca offset the expected prolonging effects on APD 90 caused by their hERG / I Kr inhibition (18) . Thus, APD 90 , a classical parameter, does not seem to be suitable for assessing the possibility that mixed ionchannel blockers will prolong APD. However, the AP assay can provide information on the inhibitory effects of mixed ion-channel blockers on various cardiac ion channels, including I Na and I Ca . In fact, we found that typical mixed ion-channel blockers such as quinidine and disopyramide shortened APD 30 and decreased APA and V max in a fashion similar to the action of Ca 2+ channel blockers that shortened APD 30 and Na + channel blockers that decreased APA and V max . These observations suggest that the advantage of the AP assay is that it can detect the effects of new chemical entities on various cardiac ion channels simultaneously, in contrast to assays focusing on a single channel expressed in a mammalian cell line such as the hERG assay.
Sensitivity and specificity of in vitro AP assay In the present in vitro AP assay, a positive response is defined as either a statistically significant increase or a greater than 10% increase from the baseline in APD 90 or APD 30-90 at a stimulation frequency of 1 Hz. Among the positive compounds, pimozide caused significant prolongation of APD 30-90 by 5% -10%, and the other positive compounds, except for terfenadine, prolonged APD 30-90 by more than 10% ( Table 2 ), indicating that the sensitivity of the in vitro AP assay was comparable to that of the hERG assay (42) . Thus, when APD 30-90 was used as an index of hERG/ I Kr -blocking activity, the sensitivity of the assay was satisfactory because the present study could detect the "positive signal" of most of the positive compounds. Since the principal purpose of the in vitro AP assay is to assess the potential risk of QT interval prolongation by new chemical entities, APD 30-90 might be a suitable parameter for screening for the risk of QT interval prolongation. However, the specificity is rather low because of the resulting increased risk of a false-positive result.
Among the negative compounds, ciprofloxacin, diphenhydramine, and propranolol prolonged APD by 5% -10%, and flecainide and verapamil prolonged the parameter by more than 10%; similar false-positive results have been observed in the hERG assay (5) . In contrast, none of negative compounds, except for flecainide and ciprofloxacin, prolonged APD 90 , indicating that the expected result for negative compounds is obtained under these conditions. Therefore, the AP assay with isolated guinea-pig papillary muscles appears to have high sensitivity and moderate specificity for assessing the potential risk of QT interval prolongation by new chemical entities when APD in combination with APD 90 is used as an index.
Failure of terfenadine to prolong APD
Terfenadine has been reported to prolong the QT interval and sometimes to cause TdP in humans (43) . Terfenadine at concentrations up to 20 µmol / L, equivalent to 9.4 µg / mL and 160 -220 times higher than the plasma concentration known to cause QT prolongation and TdP in humans (43), did not prolong APD 90 or APD at any stimulation frequency tested (Appendix 1-10), although the compound is well known to potently block I Kr (3, 10) and hERG K + current (5, 18, 28, 36) with IC 50 values in the nanomolar range. This observation is consistent with previous reports that terfenadine fails to prolong APD in various cardiac tissue preparations, including guinea-pig papillary muscle (5) and ventricle (44) , rabbit ventricle and Purkinje fibers (45) , and canine Purkinje fibers (17) . In contrast, terfenadine is reported to prolong APD in enzymatically isolated single ventricular cells (10, 15) . Although the precise reason why terfenadine did not prolong APD in cardiac tissue preparations is unclear, it is possible that terfenadine could not penetrate to its site of action in the interior of the preparations. Recently, the tissue concentration of terfenadine in the left ventricle of isolated rabbit Langendorff hearts was reported to increase to approximately 250-fold after a 3-h period of terfenadine perfusion (46) . The tissue concentration of terfenadine in the present study might not have been high enough to cause APD prolongation because of the limited perfusion period of 30 min. This possibility is supported by our observation that terfenadine at any concentration did not decrease V max at any stimulation frequency, even though the compound is reported to significantly decrease V max at 10 µmol / L and more in guinea-pig papillary muscles (44) due to its I Na -blocking activity (47) . Further study is needed to elucidate the precise reason for the lack of the expected prolongation of APD by terfenadine in guinea-pig papillary muscles.
Limitations of the in vitro AP assay
The in vitro AP assay with the guinea-pig papillary muscles has the advantages of lower cost and easier specimen handling compared to assays with isolated canine Purkinje fibers. However, the assay has several limitations. First, it is unsuitable for assessing the effects of a test compound on the transient outward K + current, I to , due to the almost complete absence of this current in guinea-pig papillary muscles (48) that is well recognized as a species difference in repolarizing K + currents (49) . Second, as shown for terfenadine, the assay cannot detect the effects of a test compound in the case of its limited accessibility to the site of action in the interior of a preparation (46) . Third, it is incapable of revealing the effects of chronic exposure to test compounds on the up-or down-regulation of ion channel proteins, as in the case of arsenic trioxide (50) or pentamidine (51) , which are reported not to block the hERG channel directly but which block the trafficking of the channel proteins to the cell surface. This, however, is a common limitation in in vitro repolarization assays.
Conclusion
When APD alone is used as an index, the sensitivity of the in vitro AP assay is satisfactory for the prediction of QT interval prolongation, although the specificity is rather low because of the "false-positive signal" given by some negative compounds. When APD 90 alone is used as an index, the expected result for the negative compounds is obtained, although the sensitivity is rather poor because of the missing "positive signal" of some positive compounds. However, when both APD and APD 90 are used as indexes, the AP assay has high sensitivity and moderate specificity for assessing the potential risk of QT interval prolongation. In addition, the AP assay is highly informative for our understanding of the effects of drugs on cardiac ion channels, because certain kinds of test compounds cause characteristic changes in the configuration of the AP. Therefore, the AP assay with isolated guinea-pig papillary muscles is expected to contribute to our ability to predict the potential risk of QT interval prolongation in humans by new chemical entities.
